Dr. Hind Hassan Al Nour

Dr. Hind Hassan Al Nour |Clyto Access

Dubai Health Authurity

Poster Presentation

Expertise: Kidney Transplantation


Dr. HIND HASSAN Al NOUR is a senior nephrologist in the renal unit of Dubai Hospital/ Dubai Health Authority since 1998 and up to present day. She has received her Medical Bachelor degree from Dubai Medical College, and then she has completed her residency in Internal Medicine and Nephrology in Dubai, United Arab Emirates. She has obtained her MRCP (UK) in 2008, attended several nephrology courses and conferences including Nephrology course in Harvard Medical School-April 2013.
She has also participate in selecting the candidates for the residency program of Dubai Health Authority and has special interest in educating medical students of Dubai Medical College. She has also been the leader in charge of the renal school; a project initiated in renal unit DUBAI HOSPITAL since 2008 and has successfully contracted up to the present day, where a multidisciplinary team take the task of educating pre dialysis patients, who are approaching end stage renal disease and requiring renal replacement therapy in near future. Dr. Al Nour has different publications and clinical research in many international journals. 


Title: Renal Cell Carcinoma of first Kidney Allograft in transplanted recipient for second time


After kidney transplantation, the use of immunosuppression therapy for the preservation of kidney function increase the incidence of malignancies in transplant recipients compared with that of the general population (1).The diagnosis tumours in renal allograft are usually accidental following ultrasonography, CT scan or MRI imaging, so special attention is important during any imaging examination of renal allograft to detect tumours as early as possible (2).In patients with the renal transplant; malignancies of the urinary tract is the second most common following skin tumour. The most affected organs prostate, kidneys, bladder and testes (3).Case report 51 years old male who had his first kidney transplantation in 1987 on the right side from living unrelated donor, he had approached ESRD in 2006 and underwent his second renal transplantation in June 2006 on the left side, again from living unrelated donor.Though he had stable kidney function, he started to have intermittent haematuria with bulging right lower loin.Ultrasound had revealed a big mass in the right transplanted kidney. CT scan with contrast demonstrated a large lobulated outlines heterogeneously enhancing mass arising from the iliac fossa of first transplanted kidney (measures 8.7x6.9x11.5cm in diameter) with local, lungs metastasis and right common iliac vein metastasis. Due to above finding patient underwent right allograft nephrectomy.
The ability to identify and prevent solid organ tumours in the transplant patient, especially early stage carcinomas depends on regular screening examinations and strict adherence to prophylactic measures. Screening of the patient and donor prior to transplantation can help to detect any underlying pre-existing malignancy (2).
Immunologic human leukocyte antigen typing and (DNA) genetic analysis should be done on each tumour specimen to detect the recipient or donor origin of the malignancy when possible (2-8).
Renal cell carcinoma is common to occur in the native kidneys after renal allograft with different incidence.
Ultrasonography of grafted kidney should be done annually for life (3).
If the tumour is small and localised; It can be treated with conservative management like radio frequency ablation or partial nephrectomy.
Total transplant nephrectomy can give a durable cure but it will return the patient to chronic dialysis.

Related Conferences :

Global Forum on Transplantation Research and Technologies